Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

Eventually, Musk reached a deal to acquire the company ... Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent ...

GSK, headquartered in Brentford, UK, is a global healthcare company with around 100,000 employees worldwide ... Flourish enters the Bay Area market with the deal. Flourish Research logo “For 30 years, ...

To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

GSK PLC closed 16.86% short of its 52-week high of £18.24, which the company reached on May 16th.

GSK PLC closed 15.88% below its 52-week high of £18.24, which the company reached on May 16th.

Bank of New York Mellon Corp grew its position in GSK plc (NYSE:GSK – Free Report) by 2.2% during the fourth quarter, ...

GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more promising than they seem. To properly understand GSK's profit results ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

A number of equities research analysts have issued reports on the company. Berenberg Bank decreased their price objective on GSK from GBX 1,820 ($23.52) to GBX 1,600 ($20.68) and set a “buy ...